medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Número 5

<< Anterior Siguiente >>

Ann Hepatol 2012; 11 (5)


Natural history of hepatitis C virus infection in a cohort of asymptomatic post-transfused subjects

Reggiardo MV, Fay F, Tanno M, García-Camacho G, Bottaso O, Ferretti S, Godoy A, Guerrita C, Paez M, Tanno F, Ruffinengo O, Benetti S, García BSE, Rossi MC, Vorobioff J, Bessone F, Tanno H

Idioma: Ingles.
Referencias bibliográficas: 45
Paginas: 658-666
Archivo PDF: 113.05 Kb.


RESUMEN

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.

  2. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003; 7: 261-87.

  3. Prieto M, Berenguer M, Rimola A, Loinaz C, Barrios C, Clemente G, et al. Liver transplantation in hepatitis C. A Spanish multicentre experience. Eur J Gastroenterol Hepatol 1998; 10: 771-5.

  4. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 1372-80.

  5. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-16.

  6. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008; 134: 1699-714.

  7. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stagespecific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-31.

  8. Fu B, Tom BD, Delahooke T, Alexander GJ, Bird SM. Eventbiased referral can distort estimation of hepatitis C virus progression rate to cirrhosis, and of prognostic influences. J Clin Epidemiol 2007; 60: 1140-8.

  9. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46.

  10. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B and type C hepatitis; a National Heart, Lung and Blood Institute collaborative study. Hepatology 2001; 33: 455-63.

  11. Wiese M, Grüngreiff K, Güthoff W, Lafrenz M, Oesen U, Porst H; East German Hepatitis C Study Group. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-a 25-year multicenter study. J Hepatol 2005; 43: 590-8.

  12. Kenny-Walsh E for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Eng J Med 1999; 340: 1228-33.

  13. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.

  14. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, NANB hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C. Hepatology 1990; 12: 671-5.

  15. Tong MJ, el-Farra NS, Reikes AR, Co RL, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6.

  16. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-95.

  17. Gordon SC, Elloway RS, Long JC, Dmuchowski CF. The pathology of hepatitis C as a function of mode of transmission: blood transfusion versus intravenous drug abuse. Hepatology 1993; 18: 1338-43.

  18. Ferenci P, Ferenci S, Datz C, Rezman I, Oberaigner W, Strauss R. Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s. J Hepatol 2007; 47: 31-6.

  19. Forns X, Ampurdanès S, Sanchez-Tapias JM, Guilera M, Sans M, Sánchez-Fueyo A, et al. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiarycare center. J Hepato 2001; 35: 265-71.

  20. Vogt M, Lang T, Frösner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcomes of hepatitis C infection in children who underwent cardiac surgery before the implementation of blooddonor screening. N Engl J Med 1999; 341: 866-70.

  21. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-6.

  22. Casiraghi MA, De Paschale M, Romanò L, Biffi R, Assi A, Binelli G, Zanetti AR. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 2004; 39: 90-6.

  23. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community- acquired hepatitis C infection in a cohort with sera stored from 1971–1975. Hepatology 2000; 32: 582-7.

  24. Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, Smoak BL, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132: 105-11.

  25. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36: S3-S20.

  26. Sobesky R, Mathurin P, Charlotte F, Meussalli J, Olivi M, Viduud M, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999; 116: 378-86.

  27. Yi Q, Wang PP, Krahn M. Improving the accuracy of longterm prognostic estimates in hepatitis C virus infection. J Viral Hepat 2004; 11: 166-74.

  28. Pradat P, Voirin N, Tillmann HL, Chevallier M, Trépo C. Progression to cirrhosis in hepatitis C patients: an agedependent process. Liver Int 2007; 27: 335-9.

  29. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.

  30. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Müllhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655-66.

  31. Tillmann HL, Chen DF, Trautwein C, Kliem V, Grundey A, Berning-Haag A, et al. Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease. Gut 2001; 48: 714-8.

  32. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet 1999; 354: 2119-24.

  33. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 729-36.

  34. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology 2002; 36: S220-S225.

  35. Safdar K, Schiff ER. Alcohol and hepatitis C. Semin Liver Dis 2004; 24: 305-15.

  36. Monto A, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, Wright TL. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 2004; 39: 826-34.

  37. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus. Hepatology 1998; 27: 1730-5.

  38. Hutchison SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a metaanalysis. Clin Gastroenterol Hepatol 2005; 3: 1150-9.

  39. Westin J, Lagging LM, Spak F, Aires N, Svensson E, Lindh M, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat 2002; 9: 235-41.

  40. Cheung O, Sterling RK, Salvatori J, Williams K, Hubbard S, Luketic VA, et al. Mild alcohol consumption is not associated with increased fibrosis in patients with chronic hepatitis C. J Clin Gastroenterol 2011; 45: 76-82.

  41. The Physician’s Guide to Helping Patients with Alcohol Problems. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism (NIAAA); 1995. NIH publication no. 95-3769.

  42. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, Realdi G. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992; 16: 273-81.

  43. Gruber A, Norder H, Magnius L, Rotzen M, Rubio C, Grillner L, Bjorkholm M. Late seroconversion and high chronicity rate of hepatitis C virus infection in patients with hematologic disorders. Ann Oncol 1993; 4: 229-34.

  44. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969-74.

  45. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med 1993; 119: 110-5.




2020     |     www.medigraphic.com